Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics. Hyaluronan is a component of the tumour extracellular matrix. Here, Chauhan et al. show that hyaluronan increases blood pressure in collagen-rich tumours by compressing vessel walls, and that reducing the level of hyaluranon with an angiotensin II inhibitor increases blood flow and drug penetrance in tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, antiangiogenic drugs have a synergistic antitumor effect in combination with radiotherapy and chemotherapy in clinical practice.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [260]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have also shown that widely prescribed ARBs can normalize the stroma and decompress blood vessels, thereby improving the outcome of chemotherapy94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
In the citing paper
“results from our laboratory have shown that the elevated levels of extracellular matrix molecules, including collagen I and hyaluronan, in such tumours can compress blood vessels, impairing their function and resulting in hypoxia94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Hyaluronan has been proposed to be the primary matrix molecule responsible for vessel compression 12 , but its exact mechanism remains unclear.”
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“This might be attributed to resistance induced by the immune microenvironment 39 .”
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628 · cited 2×
“We then studied oxygenation using phosphorescence quenching microscopy 35 .”
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · cited 2×
“…data notwithstanding, it should be noted that antiangiogenic therapy with bevacizumab has failed to prolong survival in desmoplastic tumours such as breast and pancreatic cancer 3 , casting doubt on a possible antiangiogenic mechanism for the benefits observed with angiotensin inhibitors.”
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943 · cited 6×
“Both hyaluronan and collagen fibres contribute to solid stress in tumours: hyaluronan does so by resisting compression, whereas collagen does so by resisting tension and confining the local microenvironment 5 .”
InfluentialSelf-citationSolid stress inhibits the growth of multicellular tumor spheroids
Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J., & Jain, R. K. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-778 · Cited by 859 · cited 1×
“Solid stress (pressure from solid tissue components) accumulates in tumours as cancer and stromal cells proliferate in a confined microenvironment created by crosslinked matrix molecules 4–6 .”
Self-citationEffects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 2×
“The matrix stores and transmits this stress throughout the tumour 7 , collapsing blood vessels to limit perfusion 8,9 .”
Self-citation
Cited by
Items 401–500 of 1,000
Meng, Q., Luo, X., Chen, J., Wang, D., Chen, E., Zhang, W., Zhang, G., Zhou, W., Xu, J., & Song, Z. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188443 · Cited by 39
Exploiting the STAT3 Nexus in Cancer-Associated Fibroblasts to Improve Cancer Therapy
Allam, A. H., Yakou, M. H., Pang, L., Ernst, M., & Huynh, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.767939 · Cited by 42
Evolving strategies and application of proteins and peptide therapeutics in cancer treatment
Mukherjee, A. G., Wanjari, U. R., Gopalakrishnan, A. V., Bradu, P., Biswas, A., Ganesan, R., Renu, K., Dey, A., Vellingiri, B., Allali, A. E., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114832 · Cited by 41
Tajaldini, M., Poorkhani, A., Amiriani, T., Amiriani, A., Javid, H., Aref, P., Ahmadi, F., Sadani, S., & Khori, V. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175991 · Cited by 40
Li, O., Li, L., Sheng, Y., Ke, K., Wu, J., Mou, Y., Liu, M., & Jin, W. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216391 · Cited by 46
High‐grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF‐1
Steins, A., van Mackelenbergh, M. G., van der Zalm, A. P., Klaassen, R., Serrels, B., Goris, S. G., Kocher, H. M., Waasdorp, C., de Jong, J. H., Tekin, C., et al. (2020) · EMBO reports · doi:10.15252/embr.201948780 · Cited by 39
“This has mainly been described to occur through changes in signaling pathways as well as collagen-induced changes to the environment (i.e., stiffness), ultimately hampering therapy delivery and promoting tumor cell invasion [42 – 44].”
Voutouri, C., Panagi, M., Mpekris, F., Stylianou, A., Michael, C., Averkiou, M. A., Martin, J. D., & Stylianopoulos, T. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000289 · Cited by 45
Self-citationCancer-Associated Fibroblast Diversity Shapes Tumor Metabolism in Pancreatic Cancer
Peiffer, R., Boumahd, Y., Gullo, C., Crake, R., Letellier, E., Bellahcène, A., & Peulen, O. (2022) · Cancers · doi:10.3390/cancers15010061 · Cited by 38
Ma, S., Zhou, J., Zhang, Y., He, Y., Jiang, Q., Yue, D., Xu, X., & Gu, Z. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b09633 · Cited by 38
Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs
Golder, M. R., Liu, J. X., Andersen, J. N., Shipitsin, M. V., Vohidov, F., Nguyen, H. V. ‐., Ehrlich, D. C., Huh, S. J., Vangamudi, B., Economides, K. D., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0279-x · Cited by 45
Aydıner, A., Çiftçi, R., & Şen, F. (2015) · Medicine · doi:10.1097/md.0000000000000887 · Cited by 38
Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore
Saavedra, J. M. (2021) · Physiology · doi:10.1152/physiol.00036.2020 · Cited by 37
Fernandez, J. L., Årbogen, S. B. S., Sadeghinia, M. J., Haram, M., Snipstad, S., TORP, S. H., Einen, C., Mühlenpfordt, M., Maardalen, M., Vikedal, K., et al. (2023) · Cancers · doi:10.3390/cancers15225415 · Cited by 43
“The resulting dense stroma creates a physical barrier that can lead to high interstitial pressure and limited drug delivery [5–7].”
BackgroundUnveiling the resistance to therapies in pancreatic ductal adenocarcinoma
Shah, A., Ganguly, K., Rauth, S., Sheree, S. S., Khan, I., Ganti, A. K., Ponnusamy, M. P., Kumar, S., Jain, M., & Batra, S. K. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101146 · Cited by 40
Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances
Zhao, L., Tang, H., & Cheng, Z. (2024) · Pharmaceuticals · doi:10.3390/ph17121724 · Cited by 40
“However, the use of sartans in non-cardiovascular contexts may face challenges due to dose-dependent hypotension, particularly in advanced liver diseases [72].”
Internalized compartments encapsulated nanogels for targeted drug delivery
Yu, J., Zhang, Y., Sun, W., Wang, C., Ranson, D., Ye, Y., Weng, Y., & Gu, Z. (2016) · Nanoscale · doi:10.1039/c5nr08895j · Cited by 37
Renin angiotensin system and its role in biomarkers and treatment in gliomas
Perdomo‐Pantoja, A., Mejía‐Pérez, S. I., Gómez‐Flores‐Ramos, L., Lara-Velazquez, M. A., Orillac, C. M., Gómez-Amador, J. L., & Wegman-Ostrosky, T. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2789-5 · Cited by 37
“Interestingly they found a lower impact on desmoplasia with lisinopril, suggesting an antidesmoplasia effect of AT2R (as ACEIs block both AT1 and AT2 receptors) [118].”
BackgroundBischof, T. S., Correa, R. E., Rosenberg, D., Dauler, E. A., & Bawendi, M. G. (2014) · Nano Letters · doi:10.1021/nl502180w · Cited by 37
Self-citationMenter, A. R., Carroll, N. M., Sakoda, L. C., Delate, T., Hornbrook, M. C., Jain, R. K., Kushi, L. H., Quinn, V. P., & Ritzwoller, D. P. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.07.008 · Cited by 37
Self-citationIske, J., Schroeter, A., Knoedler, S. A., Nazari‐Shafti, T. Z., Wert, L., Roesel, M. J., Hennig, F., Niehaus, A., Kuehn, C., Ius, F., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1272945 · Cited by 37
Boosting antitumor efficacy of nanoparticles by modulating tumor mechanical microenvironment
Zhang, X., Zhang, X., Yong, T., Gan, L., & Yang, X. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105200 · Cited by 40
“73 – 77 Biological methods ECM-degrading enzymes such as collagenase, matrix metalloproteinases (MMPs), hyaluronidase, and bromelain, had been utilized to modulate the tumor mechanical microenvironment and enhance the therapeutic ef fi cacy of nanomedicines.”
MethodYang, Y., Kim, J., Park, H., Lee, E., & Yoon, K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13202 · Cited by 41
Mpekris, F., Papaphilippou, P. C., Panagi, M., Voutouri, C., Michael, C., Charalambous, A., Dinev, M. M., Katsioloudi, A., Prokopi, M., Anayiotos, A. S., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c03305 · Cited by 37
Self-citationKalli, M., Mpekris, F., Charalambous, A., Michael, C., Stylianou, C., Voutouri, C., Hadjigeorgiou, A. G., Papoui, A., Martin, J. D., & Stylianopoulos, T. (2024) · Communications Biology · doi:10.1038/s42003-024-07268-1 · Cited by 37
“WepretreatedmicebearingMIA PaCa-2orKPCtumorswithdaily40mg/kglosartan(i.p.)for3dayspriorto chemotherapyadministrationtonormalizeTMEandrestorevessel functionality 17 anduntiltheendofthetreatmentprotocol.”
InfluentialSelf-citationLiu, Y., Kim, Y. J., Siriwon, N., Rohrs, J. A., Yu, Z., & Wanga, P. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26566 · Cited by 36
Realizing Cancer Precision Medicine by Integrating Systems Biology and Nanomaterial Engineering
Joo, J. I., Choi, M., Jang, S., Choi, S. R., Park, S., Shin, D., & Cho, K. (2020) · Advanced Materials · doi:10.1002/adma.201906783 · Cited by 37
Gouardères, S., Mingotaud, A., Vicendo, P., & Gibot, L. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1814735 · Cited by 37
“Among them, let’s cite hormones like relaxin [21], enzymes like collagenases 13 [22], angiotensin inhibitor called losartan [23], the antibody simtuzumab to inhibit the lysyl oxidase14 like 2 (LOXL2) [24].”
BackgroundLan, H., We, Z., Jin, K., Liu, Y., & Wang, Z. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1809559 · Cited by 39
Remodeling tumor microenvironment with nanomedicines
Martin, J. D., Miyazaki, T., & Cabral, H. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1730 · Cited by 42
Self-citationThe Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia
Gallez, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.853568 · Cited by 37
“Finally, considering that tumor hypoxia is associated with an abnormal vascularization, the impaired delivery of drugs also contributes as mechanism of resistance to the response to chemotherapy (Jain, 1991; Eskey et al., 1994; Netti et al., 1995; Jain, 1996; Jain, 1997; Tong et al., 2004; Ansiaux et al., 2006a; Marti…”
BackgroundClinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 38
“blood vessels, enhance drug delivery, and augment the anti-tumor effect of chemotherapy primarily through blockade of an angiotensin II receptor [46].”
BackgroundZhang, X., Zhu, R., Yu, D., Wang, J., Yan, Y., & Xu, K. (2023) · Cell Proliferation · doi:10.1111/cpr.13592 · Cited by 37
“138,139 During the cancer treatment process, tumour cells may escape In human intrahepatic cholangiocarcinoma, 105 vascular-derived vCAFs have been found to be strongly associated with tumour cells through the IL-6/IL-6R axis, which not only promote the occurrence of tumours but also further…”
BackgroundAngeli, S., Neophytou, C., Kalli, M., Stylianopoulos, T., & Mpekris, F. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1564626 · Cited by 41
Self-citationBahmani, B., Uehara, M., Ordikhani, F., Li, X., Jiang, L., Banouni, N., Ichimura, T., Kasinath, V., Eskandari, S. K., Annabi, N., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.030 · Cited by 34
Chang, C.-S., Seibel, A. J., Avendano, A., Cortes-Medina, M. G., & Song, J. W. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901399 · Cited by 36
Dahlgren, D., & Lennernäs, H. (2020) · Molecules · doi:10.3390/molecules25122861 · Cited by 39
“Approaches for normalizing tumour ECM and vessels are based on remodeling the tumour microenvironment to have the properties of healthy tissue rather than completely destroying the ECM components [29,32].”
BackgroundPiscatelli, J. A., Ban, J., Lucas, A. T., & Zamboni, W. C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010114 · Cited by 36
da Silva, W., Costa, P. A. C., Scalzo, S., Ferreira, H. A. S., Prazeres, P. H. D. M., Campos, C., Alves, M. T. R., da Silva, N. J. A., Santos, A. L. D. C., Guimarães, L. C., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s452896 · Cited by 36
“25,26,59 Our findings reveal that treatment with Los and Ang (1–7) reduced collagen I deposition and increased blood perfusion within the tumor, improving the functional delivery and antitumor effect of LNP-TRAIL.”
BackgroundTargeting Inflammation to Improve Tumor Drug Delivery
Gkretsi, V., Zacharia, L. C., & Stylianopoulos, T. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.07.006 · Cited by 36
Self-citationAkinpelu, A., Akinsipe, T., Avila, L. A., Arnold, R. D., & Mistriotis, P. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10166-x · Cited by 38
“Their research revealed that the branch channel with the higher resistance triggers the TRPM7-mediated influx of Ca 2+ , resulting in the local formation of a thicker cortical actin network enriched with elevated levels of myosin II-A.”
Mierke, C. T. (2024) · Biomolecules · doi:10.3390/biom14020184 · Cited by 34
The extracellular matrix in inflammation and cancer
Zhang, W., Xiang, Y., Lu, C., Wang, F., Ren, H., Wu, H., & Yan, M. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00415-6 · Cited by 37
Wang, Z. J., Arif‐Tiwari, H., Zaheer, A., Ameli, S., Bhosale, P., Do, R. K., Goenka, A. H., Guimares, A. R., Sangster, G. P., Soloff, E. V., et al. (2020) · Abdominal Radiology · doi:10.1007/s00261-020-02723-z · Cited by 36
Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence
Sántha, P., Lenggenhager, D. M., Finstadsveen, A. V., Dorg, L. T., Tøndel, K., Amrutkar, M., Gladhaug, I. P., & Verbeke, C. S. (2021) · Cancers · doi:10.3390/cancers13040895 · Cited by 34
Stromal disruption facilitating invasion of a ‘nano-arsenal’ into the solid tumor
Fu, Y., Saraswat, A. L., Monpara, J. D., & Patel, K. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.015 · Cited by 33
Angiotensin blockade therapy and survival in pancreatic cancer: a population study
Keith, S. W., Maio, V., Arafat, H. A., Alcusky, M. J., Karagiannis, T., Rabinowitz, C., Lavu, H., & Louis, D. Z. (2022) · BMC Cancer · doi:10.1186/s12885-022-09200-4 · Cited by 33
Alterations of Cytoskeleton Networks in Cell Fate Determination and Cancer Development
Wang, E. J.-Y., Chen, I., Kuo, B. Y.-T., Yu, C., Lai, M., Lin, J., Lin, L. Y.-T., Chen, C., Hwang, T., & Sheu, J. J. (2022) · Biomolecules · doi:10.3390/biom12121862 · Cited by 41
Cancer‐associated fibroblasts: Is it a key to an intricate lock of tumorigenesis?
Aden, D., Zaheer, S., Ahluwalia, H., & Ranga, S. (2023) · Cell Biology International · doi:10.1002/cbin.12004 · Cited by 33
“…properties of the collagen matrix (Olive et al., 2009; Provenzano et al., 2012), and also due to elevated interstitial fluid pressure and hypoperfusion by compressing lymphatics and blood vessels, respectively (Chauhan et al., 2013; Martin et al., 2019; Stylianopoulos et al., 2012).”
BackgroundAdvances in nuclei targeted delivery of nanoparticles for the management of cancer
Goyal, P., & Malviya, R. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188881 · Cited by 33
Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities
Min, K. K. M., Ffrench, C. B., Jessup, C. F., Shepherdson, M., Barreto, S. G., & Bonder, C. S. (2023) · Cancers · doi:10.3390/cancers15082354 · Cited by 40
Zhang, L., Wang, Y., Xia, T., Yu, Q., Zhang, Q., Yang, Y., Cun, X., Lu, L., Gao, H., Zhang, Z., et al. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1132798 · Cited by 32
“, 2011) and increase the oxygen intensity of tumor tissues as well (Chauhan et al., 2013), it could be deduced that application of losartan might also down-regulate the expression of LOX, which indicating inhibition of the cross-linking and expression of collagen I.”
BackgroundMethodResultInfluentialChen, S.-C., Wu, P.-C., Wang, C.-Y., & Kuo, P.-L. (2020) · Scientific Reports · doi:10.1038/s41598-020-70694-8 · Cited by 36
Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid
Tsiailanis, A. D., Renziehausen, A., Kiriakidi, S., Vrettos, E. I., Markopoulos, G. S., Sayyad, N., Hirmiz, B., Aguilar, M., Borgo, M. P. D., Kolettas, E., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.08.007 · Cited by 33
Shen, Y., Zou, Y., Bie, B., & Lv, Y. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301080 · Cited by 32
Chen, Z., Kang, F., Xie, C., Liao, C., Li, G., Wu, Y., Lin, H., Zhu, S., Hu, J., Lin, C., et al. (2023) · Advanced Science · doi:10.1002/advs.202303814 · Cited by 41
Endothelial Thermotolerance Impairs Nanoparticle Transport in Tumors
Bagley, A. F., Scherz‐Shouval, R., Galie, P. A., Zhang, A. Q., Wyckoff, J. B., Whitesell, L. J., Chen, C. S., Lindquist, S. L., & Bhatia, S. N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0325 · Cited by 31
“Lastly, modifications to the extracellular matrix, particularly collagen, can independently modify drug transport.[49-53] In our model, we observed retention of macromolecules in regions with higher collagen density (Supp.”
Facing the future: challenges and opportunities in adoptive T cell therapy in cancer
Magalhaes, I., Carvalho‐Queiroz, C., Hartana, C. A., Kaiser, A. M., Lukic, A., Mints, M., Nilsson, O., Grönlund, H., Mattsson, J., & Berglund, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1608179 · Cited by 32
“increases oxygen and drug delivery into the tumor [115].”
BackgroundInfluentialA Tumor Microenvironment Destroyer for Efficient Cancer Suppression
Yao, H., Xu, K., Zhou, J., Zhou, L., & Wei, S. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01544 · Cited by 32
Balsano, R., Kruize, Z., Lunardi, M., Comandatore, A., Barone, M., Cavazzoni, A., Cecconi, A. D. R., Morelli, L., Wilmink, H. W., Tiseo, M., et al. (2022) · Cells · doi:10.3390/cells11172671 · Cited by 31
“In addition, stroma stiffness reduces tumor perfusion and oxygen release, creating a favorable environment for immune escape and metastasis [33].”
BackgroundLu, Y., Lian, S., Ye, Y., Yu, T., Liang, H., Cheng, Y., Xie, J., Zhu, Y., Xie, X., Yu, S., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.020 · Cited by 34
Tang, Y., Liu, Y., Wang, S., Tian, Y., Li, Y., Teng, Z., & Lu, G. (2019) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-00610-1 · Cited by 33
Poyia, F., Neophytou, C. M., Christodoulou, M., & Papageorgis, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179555 · Cited by 33
“Interestingly, tumors were significantly smaller in mice administrated with losartan combined with either 5-FU or Doxorubicin instead of pancreatic tumors treated with one of them as a monotherapy [49,50].”
BackgroundMetabolic and immune crosstalk between cancer-associated fibroblasts and pancreatic cancer cells
Zhang, Q., Cao, Z., Yan, S., Chen, B., Wu, H., Cao, H., Chen, L., & Liu, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07164-0 · Cited by 37
“Both losartan and PEGPH20 target collagen deposition in myCAFs and improve drug delivery in preclinical models [140, 141].”
The use of drugs acting on the renin–angiotensin system and the incidence of pancreatic cancer
Mandilaras, V., Bouganim, N., Yin, H., Asselah, J., & Azoulay, L. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.375 · Cited by 30
“…and animal studies have shown that the use of ACEIs or ARBs inhibited tumour growth by inhibiting angiogenesis or inducing apoptosis (Fujimoto et al, 2001; Arafat et al, 2007; Noguchi et al, 2009; Doi et al, 2010; Fendrich et al, 2010; Arnold et al, 2012; Chauhan et al, 2013; Masamune et al, 2013).”
BackgroundInfluentialFibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction
Juillerat‐Jeanneret, L., Aubert, J., Mikulic, J., & Golshayan, D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00294 · Cited by 30
Qiao, Z.-W., Jiang, Y., Wang, L., Wang, L., Jiang, J., Zhang, J., & Mu, P. (2021) · BMC Cancer · doi:10.1186/s12885-021-08730-7 · Cited by 30
“On the contrary, AGTR1 antagonists can suppress the angiogenesis, migration and invasion of lung adenocarcinoma [22, 23].”
RetractedXiao, Z., Cai, Y., Wang, X., Hu, L., Lin, M., Zhu, K., Wang, Y., & Shuai, X. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101490 · Cited by 31
SARS-CoV-2 infection as a potential risk factor for the development of cancer
Ogarek, N., Oboza, P., Olszanecka‐Glinianowicz, M., & Kocełak, P. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1260776 · Cited by 31
Di, J., Yu, J., Ye, Y., Ranson, D., Jindal, A., & Gu, Z. (2015) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-015-0390-y · Cited by 30
Losartan treatment attenuates tumor-induced myocardial dysfunction
Stevens, S. C. W., Velten, M., Youtz, D. J., Clark, Y. Y., Jing, R., Reiser, P. J., Bicer, S., Devine, R. D., McCarthy, D. O., & Wold, L. E. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.05.007 · Cited by 31
“24 models.(45) Therefore, another plausible explanation for the observed Losartan associated prevention of tumor-associated development of cardiac dysfunction could be linked to direct effects of Losartan on tumor cells and the tumor itself.”
Multistep, effective drug distribution within solid tumors
Shemi, A., Khvalevsky, E. Z., Gabai, R. M., Domb, A. J., & Barenholz, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5051 · Cited by 32
“As the cores of tumors are nearly avascular, the absence of functional lymphatic vessels results in interstitial hypertension [9].”
BackgroundNot only tumor but also therapy heterogeneity
Garattini, S. K., Nerini, I. F., & D’Incalci, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx646 · Cited by 34
Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment
Atkinson, S. P., Andreu, Z., & Vicent, M. J. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8010006 · Cited by 32
“Strategies include treatment with nitric oxide (NO) [92,93], angiotensin II [94,95] and carbon monoxide [96,97], amongst many others (Reviewed in Maeda et al.”
BackgroundHu, X., Peng, X., Zhang, Y., Fan, S., Liu, X., Song, Y., Ren, S., Chen, L., Chen, Y., Wang, R., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155214 · Cited by 32
Fujimoto, H., Yoshihara, M., Rodgers, R. J., Iyoshi, S., Mogi, K., Miyamoto, E., Hayakawa, S., Hayashi, M., Nomura, S., Kitami, K., et al. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10169-8 · Cited by 31
“As the metastatic tumor grows, it needs more blood supply because of the increasing demand of oxygen and other nutrients of the cancer cells [128].”
BackgroundInfluentialZaremba-Czogalla, M., Jaromin, A., Sidoryk, K., Zagórska, A., Cybulski, M., & Gubernator, J. (2020) · Materials · doi:10.3390/ma13245813 · Cited by 32
Pancreatic stellate cells - rising stars in pancreatic pathologies
Hrabák, P., Kalousová, M., Krechler, T., & Zima, T. (2021) · Physiological Research · doi:10.33549//physiolres.934783 · Cited by 42
Thiery, J. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00103 · Cited by 33
“00103 Page 611 reducing hypoxia in breast and pancreatic cancer models [281].”
BackgroundSmart biomaterials for enhancing cancer therapy by overcoming tumor hypoxia: a review
Salim, S. A., Salaheldin, T. A., Elmazar, M. M., Abdel-Aziz, A. F., & Kamoun, E. A. (2022) · RSC Advances · doi:10.1039/d2ra06036a · Cited by 31
Benkhaled, S., Peters, C., Jullian, N., Arsenijevic, T., Navez, J., Gestel, D. V., Moretti, L., Laethem, J. V., & Bouchart, C. (2023) · Cancers · doi:10.3390/cancers15030768 · Cited by 30
Positron emission tomography imaging sheds new light on hypoxia and antitumor therapies
Fang, H., Wang, X., Lan, X., & Jiang, D. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230002 · Cited by 31
Nieskoski, M. D., Marra, K. A., Gunn, J. R., Kanick, S. C., Doyley, M. M., Hasan, T. G., Pereira, S. P., Trembly, B. S., & Pogue, B. W. (2017) · Journal of Biomechanical Engineering · doi:10.1115/1.4036392 · Cited by 31
“[10] has shown that both hyaluronic acid and collagen contribute to reduced vascular patency in tumors with enhanced desmoplasia; however, collagen played the dominant role in vessel collapse.”
BackgroundMethodInfluentialRamu, I., Buchholz, S. M., Patzak, M. S., Goetze, R. G., Singh, S. K., Richards, F. M., Jodrell, D. I., Sipos, B., Ströbel, P., Ellenrieder, V., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.024 · Cited by 30
Kashkooli, F. M., Bhandari, A., Gu, B., Kolios, M. C., Kohandel, M., & Zhan, W. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114138 · Cited by 35
Chen, J., Li, S., Liu, X., Liu, S., Xiao, C., Zhang, Z., Li, S., Li, Z., & Yang, X. (2021) · Nanoscale · doi:10.1039/d1nr01552d · Cited by 29
Bian, S., Dong, H., Zhao, L., Li, Z., Chen, J., Zhu, X., Qiu, N., Jia, X., Song, W., Li, Z., et al. (2022) · Advanced Science · doi:10.1002/advs.202201931 · Cited by 30
Angiotensin II inhibitor facilitates epidermal wound regeneration in diabetic mice
eKamber, M., Papalazarou, V., Rouni, G., Papageorgopoulou, E., Papalois, A., & Kostourou, V. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00170 · Cited by 30
“Our data agree with studies showing that Losartan can decrease profibrotic signals by inhibiting thrombospondin -1 and transforming growth factor (TGF)-β1 action and downregulating connective tissue growth factor (CCN2) (Chauhan et al., 2013).”
ResultRestriction of drug transport by the tumor environment
Nandigama, R., Upcin, B., Aktas, B. H., Ergün, S., & Henke, E. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1744-z · Cited by 31
Sousa-Junior, A. A., Mendanha, S. A., Carrião, M. S., Capistrano, G., Prospero, A. G., Soares, G. A., Cintra, E. R., Santos, S. F. O., Zufelato, N., Alonso, A., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01094 · Cited by 32
Nanomedicine and chemotherapeutics drug delivery: challenges and opportunities
Nezhadi, S., Saadat, E., Handali, S., & Dorkoosh, F. A. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1808000 · Cited by 30
“According to the preclinical studies, normalising vessel leakiness can increase intertumoural transport of oxygen and NPs (up to at 40 nm in diameters) in comparison to CAFs and ECM normalisation that enhances the delivery of NPs of all sizes, up to 125 nm [4,68,115].”
BackgroundLiu, X., Yang, J., Huang, S., Hong, Y., Zhu, Y., Wang, J., Wang, Y., Liang, T., & Bai, X. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.023 · Cited by 30
Improving Tumor Targeting and Penetration for Nanoparticle‐Mediated Cancer Therapy
Luo, Z., Chen, C., & Li, S. (2025) · Small Methods · doi:10.1002/smtd.202401860 · Cited by 31
The plasticity of cancer-associated fibroblasts
Xia, Z., & Wever, O. D. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.04.012 · Cited by 32
Yarmoska, S. K., Yoon, H., & Emelianov, S. (2019) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2019.02.009 · Cited by 28
Huo, T., Zhang, X., Qian, M., Nie, H., Liang, D., Lin, C., Yang, Y., Guo, W., Lächelt, U., & Huang, R. (2022) · Advanced Science · doi:10.1002/advs.202200608 · Cited by 29
Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors
Askoxylakis, V., Arvanitis, C., Wong, C. S. F., Ferraro, G. B., & Jain, R. K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.011 · Cited by 28
“Reduction of collagen and hyaluronic acid has been shown to reduce solid stress, decompress vessels and enhance the efficacy of anti-cancer therapies [222,223].”
BackgroundSelf-citationA cerebellar window for intravital imaging of normal and disease states in mice
Askoxylakis, V., Badeaux, M. D., Roberge, S., Batista, A., Kirkpatrick, N., Snuderl, M., Amoozgar, Z., Seano, G., Ferraro, G. B., Chatterjee, S., et al. (2017) · Nature Protocols · doi:10.1038/nprot.2017.101 · Cited by 28
Self-citationPharmacokinetics and Tissue Transport of Intraperitoneal Chemotherapy
Lagast, N., Carlier, C., & Ceelen, W. P. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2018.02.003 · Cited by 31
Li, W., Li, S., Chen, I. X., Liu, Y., Ramjiawan, R. R., Leung, S. C. H., Gerweck, L. E., Fukumura, D., Loeffler, J. S., Jain, R. K., et al. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01775-9 · Cited by 32
Self-citationSun, X., Zhou, Y. Y., Sun, S., Qiu, S., Peng, M., Gong, H., Guo, J., Wen, C., Zhang, Y., Xie, Y., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00737-1 · Cited by 27
Metadata
- Authors
- Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., Popović, Z., Huang, P., Bawendi, M. G., Boucher, Y., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-10-01
- Volume
- 4
- Issue
- 1
- Pages
- 2516-2516
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3806395
- OpenAlex
- W1603491949
- Cited by
- 1,031
- References
- 64
- Citations by year
- 2026: 85 · 2025: 77 · 2024: 86 · 2023: 101 · 2022: 96 · 2021: 128 · 2020: 92 · 2019: 82 · 2018: 66 · 2017: 69 · 2016: 56 · 2015: 54 · 2014: 31 · 2013: 7
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- Lustgarten Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (1s10rr027070-01, W81XWH, CA080124, CA085140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, T32CA073479, R01CA085140, P01-CA126642, R01-CA11576, P01CA080124, R01CA126642, R01CA098706)
- National Institute of Biomedical Imaging and Bioengineering (P41EB015903)
- National Center for Research Resources (S10-RR027070)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- losartan, hyaluronic acid, tumor stroma, solid stress, collagen, TGF-β1, connective tissue growth factor, endothelin-1, drug delivery, tumor hypoxia, chemotherapy potentiation, breast cancer, pancreatic cancer, drug repurposing
- MeSH terms
- Angiotensins, Animals, Antineoplastic Agents, Collagen, Drug Synergism, Female, Fluorouracil, Humans, Hyaluronic Acid, Mammary Neoplasms, Experimental, Pancreatic Neoplasms, Stress, Mechanical, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Stromal Cells, Endothelin-1, Losartan, Mechanotransduction, Cellular, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers, Mice, Transforming Growth Factor beta1, Connective Tissue Growth Factor, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.